Curi RMB Capital’s Castle Biosciences CSTL Stock Holding History

Curi RMB Capital’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,423	Closed	-$431K	–	476
2020 Q4	$431K	Buy	+6,423	New	+$348K	0.02%	449

Other funds holding CSTL

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return

Curi RMB Capital's CSTL Position: Q1 2021 in Review

Curi RMB Capital sold out of Castle Biosciences (CSTL) in Q1 2021, closing a stake of 6,423 shares — an estimated $431K sold.

Curi RMB Capital first reported a position in CSTL in Q4 2020 and held it in 1 quarter. The position peaked at $431K in Q4 2020. 175 funds tracked by Wall St. Rank hold CSTL as of Q1 2021.

Curi RMB Capital reported no remaining Castle Biosciences position as of Q1 2021 after selling out during the quarter.
Curi RMB Capital sold 6,423 Castle Biosciences shares in Q1 2021, an estimated $431K.
Curi RMB Capital first reported a position in Castle Biosciences in Q4 2020 and held it in 1 quarter.
Curi RMB Capital's Castle Biosciences position peaked at $431K in Q4 2020.
175 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2021.

Based on Curi RMB Capital's 13F filing for Q1 2021, filed 12 May 2021.